These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 33395067

  • 1. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
    Zhao F, Feng G, Zhu J, Su Z, Guo R, Liu J, Zhang H, Zhai Y.
    Anticancer Drugs; 2021 Apr 01; 32(4):386-393. PubMed ID: 33395067
    [Abstract] [Full Text] [Related]

  • 2. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y.
    Biomed Pharmacother; 2020 May 01; 125():110033. PubMed ID: 32187962
    [Abstract] [Full Text] [Related]

  • 3. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 4. The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
    Wang J, Wei H, Huang Y, Chen D, Zeng G, Lian Y, Huang Y.
    Aging (Albany NY); 2019 Aug 13; 11(15):5769-5785. PubMed ID: 31409760
    [Abstract] [Full Text] [Related]

  • 5. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
    Wang D, Yang J.
    Acta Biochim Pol; 2023 Apr 17; 70(2):239-246. PubMed ID: 37068178
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
    Yuan H, Li AJ, Ma SL, Cui LJ, Wu B, Yin L, Wu MC.
    World J Gastroenterol; 2014 May 07; 20(17):4953-62. PubMed ID: 24833845
    [Abstract] [Full Text] [Related]

  • 7. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT, Shu ZY, Jiang JH, Xie QF, Zheng SS.
    Hepatobiliary Pancreat Dis Int; 2020 Dec 07; 19(6):547-554. PubMed ID: 33051131
    [Abstract] [Full Text] [Related]

  • 8. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
    Ceballos MP, Angel A, Delprato CB, Livore VI, Ferretti AC, Lucci A, Comanzo CG, Alvarez ML, Quiroga AD, Mottino AD, Carrillo MC.
    Eur J Pharmacol; 2021 Feb 05; 892():173736. PubMed ID: 33220273
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
    Wang X, Li H, Li D, Bai Y, Zhang Y, Yan X, Li J, Zhao R, Liu J, Liu W, Shi M, Xu C, Yang T, Zhang T.
    FEBS Open Bio; 2021 Jan 05; 11(1):133-145. PubMed ID: 33176070
    [Abstract] [Full Text] [Related]

  • 10. Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma.
    Lin CH, Elkholy KH, Wani NA, Li D, Hu P, Barajas JM, Yu L, Zhang X, Jacob ST, Khan WN, Bai XF, Noonan AM, Ghoshal K.
    Mol Cancer Ther; 2020 Feb 05; 19(2):384-396. PubMed ID: 31582534
    [Abstract] [Full Text] [Related]

  • 11. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Ma Y, Xu R, Liu X, Zhang Y, Song L, Cai S, Zhou S, Xie Y, Li A, Cao W, Tang X.
    Int J Med Sci; 2021 Feb 05; 18(6):1456-1464. PubMed ID: 33628103
    [Abstract] [Full Text] [Related]

  • 12. Effect of Combined Sorafenib/Cisplatinum Treatment on the Autophagy and Proliferation of Hepatocellular Carcinoma hepG2 Cells in Vitro.
    Wang Y, Wang L.
    Asian Pac J Cancer Prev; 2020 Oct 01; 21(10):2853-2857. PubMed ID: 33112540
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.
    Int J Cancer; 2012 Aug 01; 131(3):548-57. PubMed ID: 21858812
    [Abstract] [Full Text] [Related]

  • 14. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
    Chen S, Du Y, Xu B, Li Q, Yang L, Jiang Z, Zeng Z, Chen L.
    Oncogene; 2021 May 01; 40(19):3378-3393. PubMed ID: 33875785
    [Abstract] [Full Text] [Related]

  • 15. Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway.
    Zhou B, Lu Q, Liu J, Fan L, Wang Y, Wei W, Wang H, Sun G.
    Int J Biol Sci; 2019 May 01; 15(9):1905-1920. PubMed ID: 31523192
    [Abstract] [Full Text] [Related]

  • 16. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
    Xu WP, Liu JP, Feng JF, Zhu CP, Yang Y, Zhou WP, Ding J, Huang CK, Cui YL, Ding CH, Zhang X, Lu B, Xie WF.
    Gut; 2020 Jul 01; 69(7):1309-1321. PubMed ID: 31727683
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells.
    Barot S, Abo-Ali EM, Zhou DL, Palaguachi C, Dukhande VV.
    Exp Cell Res; 2019 Aug 15; 381(2):288-300. PubMed ID: 31128107
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy.
    Zhang JQ, Li YM, Liu T, He WT, Chen YT, Chen XH, Li X, Zhou WC, Yi JF, Ren ZJ.
    World J Gastroenterol; 2010 Sep 14; 16(34):4281-90. PubMed ID: 20818811
    [Abstract] [Full Text] [Related]

  • 19. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
    Xue ST, Li K, Gao Y, Zhao LY, Gao Y, Yi H, Jiang JD, Li ZR.
    Autophagy; 2020 Oct 14; 16(10):1823-1837. PubMed ID: 31986961
    [Abstract] [Full Text] [Related]

  • 20. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
    Feng J, Dai W, Mao Y, Wu L, Li J, Chen K, Yu Q, Kong R, Li S, Zhang J, Ji J, Wu J, Mo W, Xu X, Guo C.
    J Exp Clin Cancer Res; 2020 Jan 30; 39(1):24. PubMed ID: 32000827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.